Company news

Elicio Therapeutics, Inc. news in 2025

Elicio Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Elicio Therapeutics Reports Antigen Spreading to Patient-Specific Neoantigens Beyond mKRAS in Ongoing Phase 2 AMPLIFY-7P Trial

December 11, 2025

Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer

November 19, 2025

Elicio Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

November 13, 2025

Elicio Therapeutics Reports Robust, Cytolytic mKRAS-Specific T Cell Responses Across Diverse Patient HLA in Ongoing Phase 2 AMPLIFY-7P Trial of ELI-002 7P and New ELI-004 Preclinical Data at SITC

November 7, 2025

Elicio Therapeutics to Present Clinical and Preclinical Data at the SITC 2025 Annual Meeting

November 3, 2025

Elicio Therapeutics Reports Robust T cell Responses Across Diverse HLA backgrounds in Ongoing Phase 2 AMPLIFY-7P Trial

October 27, 2025

Elicio Therapeutics Announces Investigator-Initiated Phase 1 Trial to be Conducted by Memorial Sloan Kettering Cancer Center and funded by The Lustgarten Foundation for Neoadjuvant ELI-002 7P in Pancreatic Ductal Adenocarcinoma

September 29, 2025

Elicio Therapeutics Reports ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable Patients in Ongoing Phase 2 AMPLIFY-7P Trial

September 17, 2025

Elicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease (“MRD”) Positive, Adjuvant-Stage Patients

August 12, 2025

Elicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

August 7, 2025

Elicio Therapeutics Announces Positive Recommendation by IDMC to Continue ELI-002 7P Randomized Phase 2 Study in Pancreatic Cancer Without Modifications to Final Analysis

August 5, 2025

Elicio Therapeutics to Host Virtual KOL Event on June 25, 2025 to Discuss AMP-Powered ELI-002 for the Treatment of KRAS mutation-driven Pancreatic Cancer

June 17, 2025

Elicio Therapeutics Secures $10 Million in Financing

June 4, 2025

Elicio Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Updates

May 13, 2025

Elicio Therapeutics Reports Inducement Grant to New Chief Strategy and Financial Officer and Other New Hires

April 16, 2025

Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates

March 31, 2025

Elicio Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer

March 24, 2025

Decks in 2025